Patient Capital Management, LLC 13F holdings and portfolio analysis
Sign in to clone a new branch from the selected plan, then continue optimizing in the new branch.
Baseline
Analysis messagesPre-generated Q&A about this fund. Use as reference context for your own analysis.
The baseline is a direct read-through of the disclosed fund portfolio. It is led by RPRX (Royalty Pharma plc) 8.58%, C 7.87%, and GOOGL (Alphabet Inc.) 7.53%, with sector exposure of Health Care 25.87%, Consumer Discretionary 18.61%, and Communication Services 17.63%. The baseline metrics show return 13.12%, alpha 0.13%, beta 1.01, Sharpe 0.71, Sortino 1.03, and max drawdown -26.07%, so this should be treated as an equity exposure with its own concentration and timing risk rather than a neutral benchmark clone.
The strongest recent period was 2024-06-30 (20.18% strategy return, 9.83% benchmark, 10.35% excess, 16.47% turnover), while the weakest was 2024-03-31 (-3.49% strategy return, 2.31% benchmark, -5.81% excess, 15.03% turnover). Those periods should be read alongside baseline metrics of return 13.12%, alpha 0.13%, beta 1.01, Sharpe 0.71, Sortino 1.03, and max drawdown -26.07% to judge whether returns came from persistent exposure or a narrow timing window.
Concentration is the first item to inspect: top 5 36.75%, top 10 63.68%, top 20 95.76%. The largest names are RPRX (Royalty Pharma plc) 8.58%, C 7.87%, GOOGL (Alphabet Inc.) 7.53%, AMZN (Amazon.com, Inc.) 6.69%, and NVDA (NVIDIA Corporation) 6.08%, and the largest sector exposures are Health Care 25.87%, Consumer Discretionary 18.61%, and Communication Services 17.63%. If those exposures reverse, baseline performance can diverge sharply from a broad index.